Evidence map›Paper›PMID 35663273›Full record

ArticleThe World Allergy Organization journal2022

Severe asthma treatment patterns: A multicenter observational study in the Gulf region.

Mona Al-Ahmad, Hassan Mobayed, Nasser Al Busaidi, Mohamed Nizam Iqbal, Saif Al Mubaihsi, Moussa Khadadah, Abeer Kassem, Mohamed Abuzakouk, Mateen Uzbeck, Ashraf Al Zaabi and 1 more

Open access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Mona Al-AhmadMicrobiology Department, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
Hassan MobayedHamad Medical Corporation, Doha, Qatar.
Nasser Al BusaidiRoyal Hospital, Muscat, Oman.
Mohamed Nizam IqbalRashid Hospital, Dubai, United Arab Emirates.
Saif Al MubaihsiSultan Qaboos University Hospital, Muscat, Oman.
Moussa KhadadahMubarak Al Kabeer Hospital, Jabriya, Hawalli, Kuwait.
Abeer KassemIbrahim Bin Hamada Obaidullah Hospital, Ras Al Khaimah, United Arab Emirates.
Mohamed AbuzakoukCleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Mateen UzbeckCleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Ashraf Al ZaabiZayed Military Hospital, Abu Dhabi, United Arab Emirates.
Hisham FaroukAstraZeneca Gulf, Dubai, United Arab Emirates.
Hamad Medical Corporation · QAKuwait University · KWMubarak Al Kabeer Hospital · KWRashid Hospital · AERoyal Hospital · OMSultan Qaboos University Hospital · OMZayed Military Hospital · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While crucial to the assessment and improvement of asthma control, insights on treatment practices in patients with severe diseases across Gulf nations are lacking. This observational study describes the treatment patterns of adolescents and adults with severe asthma across four countries of the Gulf region and evaluates current levels of asthma control; quality of life (QoL); exacerbation frequency; and the application of cellular, protein, and respiratory biomarkers in assessing asthma severity and inflammation. Methods: Patients (aged >12 years, body weight ≥40 kg) with clinician-diagnosed, severe asthma (guided by the 2018 Global Initiative for Asthma definition) were included in this cross-sectional, multicenter, observational study conducted in the four Gulf countries of Kuwait, Oman, Qatar, and the United Arab Emirates. Data on demographics, treatment patterns, and laboratory parameters (blood eosinophil count [BEC], levels of serum immunoglobulin E [IgE], and fractional exhaled nitric oxide [FeNO]) were extracted from the medical records of patients during a 12-month retrospective period and transcribed onto case report forms. At the Enrollment visit, patients assessed their asthma control and QoL with the self-administered Asthma Control Questionnaire (ACQ) and a standardized version of the Asthma Quality of Life Questionnaire (AQLQ(S)), respectively. Results: Among the 243 patients analyzed, (mean [standard deviation (SD)] age, 48.4 [13.9] years; female, 67.5%), the inhaled corticosteroid (ICS)/long-acting β Conclusions: Despite recommended ICS/LABA therapy being prescribed to most patients for their severe disease, the majority experienced uncontrolled asthma and exhibited elevated BECs. These findings indicate the need for enhanced treatment strategies to improve and sustain asthma control in the Gulf region.

Indexed as

Asthma controlBiomarkersGulfQuality of lifeSevere asthma

Identifiers

PMID35663273
PMCPMC9127696
OpenAlexW4280639455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.